Who’s attending?

The event has surpassed our expectations on seniority and companies - this means the discussions are going to be much better and more meaningful in terms of change that benefits patients.

As it stands:

  • 58% of attendees are at director level and above

  • 62% of attendees are from big pharma.

Here is a selection of job titles and companies that are amongst the confirmed attendees for the first annual D4 event in Cambridge, MA.


Companies

  • AbbVie

  • Biogen

  • Eli Lilly and Company

  • Alexion Pharmaceuticals, Inc

  • Alnylam Pharmaceuticals

  • Astellas

  • AstraZeneca

  • Biogen

  • Bristol-Myers Squibb

  • Celgene

  • Eisai

  • enEvolv

  • FDA

  • Genentech

  • Goldfinch Bio

  • GSK

  • Intarcia

  • Klogene Therapeutics Inc.

  • Merck

  • Novartis

  • OSTHUS Inc.

  • PAREXEL 

  • Pfizer

  • Regeneron

  • Roche

  • Sanofi

  • Seres Therapeutics

  • Takeda Pharmaceuticals

  • Vedanta Biosciences

Job Titles

  • Vice President

  • Director, Genomic Biomarkers

  • Principal Research Investigator / NGS pipeline Lead

  • Global Area Head, Technical Solution Delivery & Architecture

  • Sr. Director

  • Sr. Scientist

  • Associate Director, Novel Capabilities & Knowledge Transformation

  • Associate Director, Partnership Office

  • Solution Architect

  • Director of App Development - Digital Devices R&D

  • Global Safety Lead

  • Head Program and Portfolio Management

  • Global Head Innovation, LLC.

  • Senior Director Technology Strategy and Innovation

  • Director, Data Sciences

  • Scientist, Biostatistics

  • Medical Director, Inflammation and Immunology

  • Head of Computational Biology

  • COO

  • Executive Director, Translational Science Oncology

  • VP, R&D, Global Operations and Global IT

  • Senior Director, Pharmacogenetics and Human Genetics